How confidential trial negotiations and agreements between the food and drug administration and sponsors marginalize local institutional review boards, and what to do about it

American Journal of Bioethics

Volumn 6, Issue 3, 2006, Pages 22-24

  Mann, Howard ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD SUBSTITUTE; HEMOGLOBIN; POLYMERIZED HEMOGLOBIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COOPERATION; DRUG INDUSTRY; ETHICS; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; NOTE; PROFESSIONAL STANDARD; RANDOMIZED CONTROLLED TRIAL; RESEARCH ETHICS; UNITED STATES;

BLOOD SUBSTITUTES; COOPERATIVE BEHAVIOR; DRUG INDUSTRY; ETHICS COMMITTEES, RESEARCH; ETHICS, RESEARCH; HEMOGLOBINS; HUMANS; INFORMED CONSENT; NEGOTIATING; RANDOMIZED CONTROLLED TRIALS; RESEARCH SUPPORT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33745074908     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265160600685663     Document Type: Note

References (10)

1. Anon. 2002. Guidance for industry. Special protocol assessment. Department of Health and Human Services. Available at: http://www.webcitation. org/query?id=1138576023249290 (Accessed March 28, 2006).
2. Kipnis, K., N. M. P. King, and R. M. Nelson. 2006. An open letter to institutional review boards Considering Northfield Laboratories' PolyHeme® trial. American Journal of Bioethics 6(3):18-21.
3. Krleža-Jeric, K. C. A. 2006. The Ottawa Statement on Trial Registration. Principles of operationalisation for international trial registration. Proposed Ottawa Group protocol items. Available at: http://www.webcitation.org/query?id=1138495824761229 (Accessed March 28, 2006).
4. Mann, H. 2002. Clinical trial protocols: Agreements between the FDA and industrial sponsors. Lancet 360(9343): 1345-1346.
5. Mann, H., A. J. London, and J. Mann. 2005. Equipoise in the enhanced suppression of the platelet IIb/IIIa receptor with integrilin trial (ESPRIT): a critical appraisal. Clinical Trials 2(3): 233-241; discussion 242-243.
6. Northfield Laboratories. 2005. PolyHeme backgrounder. Available at: http://www.webcitation.org/query?id=1138468571518009 (Accessed March 28, 2006).
7. O'Shea, J. C., G. E. Hafley, S. Greenberg, V. Hasselblad, T. J. Lorenz, M. M. Kitt, J. Strony, and J. E. Tcheng. 2001. Platelet glycoprotein IIb/IIIa receptor blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA 285: 2468-2473.
8. Tcheng, J. E., M. Madan, J. C. O'Shea, E. A. Cohen, C. E. Buller, A. M. Lincoff, J. J. Popma, P. S. Teirstein, M. M. Kitt, T. J. Lorenz, S. Greenberg, N. Fost, and R. M. Califf. 2003. Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention. Journal of Interventional Cardiology 16:97-105.
9. U.S. Food and Drug Administration. 1998. Guidance for Institutional Review Boards and Clinical Investigators. 1998 Update. Sponsor-Investigator-IRB Interrelationship. Available at: http://www.webcitation.org/query?id= 1138665117132495 (Accessed March 28, 2006).
10. Wood, A., C. Grady, and E. Emanuel. 2004. Regional ethics organizationsfor protection of human research participants. Nature Medicine 10(12): 1283-1288.